← Back to headlines
Citi Initiates Alnylam Pharmaceuticals with Buy Rating
Citi has begun coverage of Alnylam Pharmaceuticals (ALNY) with a 'Buy' rating, signaling a positive investment recommendation for the biotech company.
25 May, 18:09 — 25 May, 18:09
Sources
Showing 1 of 1 sources
